Regulatory

Aug 05, 2016
Having lobbied hard to have Inter Partes Review proceedings (IPRs) enacted, the tech industry may now be regretting what it wished for, write Traci Medford-Rosow and Peter C. Richardson.
Jul 27, 2016
Stakeholders are looking to move up the Prescription Drug User Fee Act timeframe to gain Congressional action before the Obama administration steps down.
Jul 27, 2016
Leela Barham looks at the EU plans for a European patent, and asks where the UK will fit in after Brexit.
Jul 20, 2016
Not yet, says Reflector. But to judge from the European Parliament's latest foray into the subject, there could be plenty of support for such an approach.
Jul 12, 2016
Pharmaceutical Executive
A look at how Europe’s new accelerated drug approval scheme can move existing review pathways to something better—and take a page from the FDA experience as well.
Jul 07, 2016
The long planned for transparency of industry payments to doctors, pharmacists, nurses and others has shone some dappled light on the UK industry, writes Leela Barham.
Jul 06, 2016
It's time for new pharma strategies to combat deadly drug-resistant infections, writes Jil Wechsler.
Jul 05, 2016
The UK's Brexit vote has unleashed turbulence in Europe — not least on its pharma sector. Reflector reports.
Jul 01, 2016
Leela Barham looks at the implications for the UK industry in the aftermath of last week's vote for Brexit.
Jun 30, 2016
FDA's Brenda Stodart outlines the services of the Agency's Small Business and Industry Assistance (SBIA) Program.
native1_300x100
lorem ipsum